EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Dialysis-dependent patients' outcomes during Covid-19 hospitalization: Early vs. late survival

Jovana Kušić-Miličević, Marija Karapandžić, Mina Stajčić, Jelena Dodić, Marija Anđelković-Apostolović, Branislav Apostolović, Rodoljub Marković, Veselinka Đurković, Danijela Momčilović-Živković, Elena Jordanova, Đorđe Inđić, Ljiljana Komadina, Nadežda Zec, Tamara Jemcov

Medicinska istrazivanja · 2025

DOI: 10.5937/medi0-56820 ↗
AbstractBibliografische Angaben

Abstract

Introduction: During the COVID-19 pandemic, receiving hemodialysis was recognized as a predictor of poor survival. This study evaluated in-hospital and late survival in patients treated with hemodialysis during COVID-19 hospitalization. Methods: This single-center retrospective study included 176 patients requiring hemodialysis during COVID-19 hospitalization. Patients were divided into three groups: acute kidney injury (AKI), acute-on-chronic kidney disease (aCKD), and chronic hemodialysis (HD). Data was collected from patients' electronic records. Results: The majority (73.3%) of the study population were chronic hemodialysis patients. The overall in-hospital mortality was high (35.8%), and differed significantly among groups: 82.1%, 57.9% and 22.5% in the AKI, aCKD, and HD patients, respectively (p<0.001). After 12 months, death occurred in almost 30% of the reached patients, of whom the majority were from the chronic hemodialysis group. Conclusion: Dialysis-dependent patients experience high mortality during COVID-19, especially those who develop AKI and aCKD. Chronic hemodialysis patients are exposed to better in-hospital survival; however, their one-year mortality remains significant.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →